EGFR Exon 19 Insertion Cancer Clinical Trials

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

826 sites for NCT02465060

AKT1 Mutation, +91 more biomarkers

Breast Carcinoma, +3 more conditions

adavosertib, +26 more drugs

immunotherapy, +1 more type

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

343 sites for NCT04181060

EGFR A763_Y764insFQEA, +12 more biomarkers

Non-Small Cell Lung Carcinoma

bevacizumab, +1 more drug

targeted therapy

Phase 2 Study of Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation

61 sites for NCT03318939

EGFR A763_Y764insFQEA, +31 more biomarkers

Non-Small Cell Lung Carcinoma

poziotinib

targeted therapy

Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer

81 sites for NCT02609776

EGFR A763_Y764insFQEA, +19 more biomarkers

Lung Adenocarcinoma, +2 more conditions

amivantamab, +3 more drugs

chemotherapy, +1 more type

A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)

151 sites for NCT03940703

EGFR A763_Y764insFQEA, +12 more biomarkers

Non-Small Cell Lung Carcinoma

osimertinib, +1 more drug

targeted therapy

Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy

10 sites for NCT04816214

EGFR A763_Y764insFQEA, +7 more biomarkers

Non-Small Cell Lung Carcinoma

capmatinib, +1 more drug

targeted therapy

Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers

11 sites for NCT04410796

EGFR A763_Y764insFQEA, +10 more biomarkers

Non-Small Cell Lung Carcinoma

carboplatin, +2 more drugs

chemotherapy, +1 more type

Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)

1 site for NCT04743505

EGFR A763_Y764insFQEA, +6 more biomarkers

Non-Small Cell Lung Carcinoma

bozitinib, +1 more drug

targeted therapy

Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)

40 sites for NCT03944772

EGFR A763_Y764insFQEA, +7 more biomarkers

Large Cell Lung Neuroendocrine Carcinoma, +2 more conditions

alectinib, +11 more drugs

chemotherapy, +2 more types

First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)

12 sites for NCT05099172

EGFR A763_Y764insFQEA, +12 more biomarkers

Non-Small Cell Lung Carcinoma

BAY2927088

targeted therapy

Study of JTX 8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumors

33 sites for NCT04669899

ALK Fusion, +11 more biomarkers

Breast Carcinoma, +3 more conditions

JTX-8064, +1 more drug

immunotherapy

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)